Disparities of Adolescent and Young Adult Patients in the Treatment of Malignant Hematologic Diseases
Dr. Isenalumhe covers disparities in the treatment of malignant hematologic diseases of the adolescent and young adult patient population.
And Then There Were 10: Dendritic Cells and Monocytes Undergo a Reclassification
Dr. Moss covers a radical revision of the classification of dendritic cells and monocytes.
Dr. Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Executive Committee Spring Retreat in Canada.
Dr. Anderson discusses ASH's plan to participate in the "March for Science" to advocate for innovation and education through adequate research funding.
Dr. Anderson offers insight into ASH's policy statements during this politically contentious time.
In his first President's Column, Dr. Kenneth Anderson speaks about ASH's commitment to education and to spreading awareness on important treatment advances and unprecedented scientific discoveries.
Kenneth C. Anderson, MD, highlights a recent trial about adult patients with relapsed and/or refractory Multiple Myeloma.
Lenalidomide Maintenance Therapy in Multiple MyelomaDr. Anderson has served on Celgene’s advisory board. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 366 1759 1769. McCarthy PL, Owzar
Microenvironment Induced Genomic Instability in Multiple MyelomaDr. Anderson indicated no relevant conflicts of interest. Koduru S, Wong E, Strowig T, et al. Dendritic cellmediated activation induced cytidine deaminase (AID) dependent induction of genomic instability in human myeloma. Blood. 2012 119
The Added Value of 18 F FDG PET CT in Defining Prognosis and Response in MyelomaDr. Anderson indicated no relevant conflicts of interest. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18 F FDG PET CT in
Delineating Molecular Mechanisms of Proteasome and Histone Deacetylase Inhibitor Induced Myeloma CytotoxicityDr. Anderson serves on advisory boards for Millennium and Novartis. Mannava S, Zhuang D, Nair JR et al. KLF9 is a novel transcriptional regulator of bortezomib and LBH589 induced
Combined Histone Deacetylase and Proteasome Inhibitor Therapy in MyelomaDr. Anderson indicated no relevant conflicts of interest. Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple
July-August 2017Volume 14, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology